Expressing support for the designation of the last Tuesday of April each year as "APOL1-Mediated Kidney Disease (AMKD) Awareness Day".
Impact
The resolution emphasizes the need for increased public awareness and understanding of kidney disease and the genetic factors that contribute to its prevalence, specifically the APOL1 gene variants. These genetic mutations increase the risk of developing AMKD, a form of kidney disease that can progress rapidly to kidney failure. By promoting awareness through a designated day, HR360 aims to encourage individuals, particularly those with ancestry linked to Western and Central Africa, to consider genetic testing and engage in preventive health measures.
Summary
HR360, also known as the APOL1-Mediated Kidney Disease Awareness Day Resolution, is a legislative proposal aimed at raising awareness regarding APOL1-mediated kidney disease (AMKD), particularly as it affects the Black community in the United States. The resolution calls for the last Tuesday of April to be designated as 'APOL1-Mediated Kidney Disease Awareness Day'. This initiative is proposed in the wake of alarming statistics, indicating that Black Americans are disproportionately affected by kidney disease, making up 30% of patients with kidney failure despite comprising only 13% of the population.
Contention
While HR360 seeks to shed light on a critical health issue, it may face challenges in garnering broader support due to differing opinions on health awareness initiatives. Some lawmakers may argue that designating a specific day may not translate into effective action or funding for necessary research and treatment developments. Additionally, there may be contention regarding how to effectively address healthcare disparities and implement measures that ensure equitable access to genetic testing and treatment for affected populations.
Notable_points
The resolution highlights the substantial economic burden of kidney disease on the Medicare program, amounting to over $45 billion annually, stressing the importance of preventive health measures. Furthermore, HR360 notes the necessity for ongoing research and clinical trials to improve understanding and treat this rapidly progressive disease, especially given that there are currently no FDA-approved treatments for individuals with APOL1-mediated kidney disease.
Expressing support for the designation of September 2025 as "National Polycystic Kidney Disease Awareness Month", and raising awareness and understanding of polycystic kidney disease.